Shangavy Pandiarajan

Ms. Shangavy Pandiarajan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
SPShangavy Pandiarajan
Shangavy Pandiarajan
SUSaranya Udayakumar
Saranya Udayakumar
GJGopalarethinam Janani
Gopalarethinam Janani
DMDevadass Jessy Mercy
Devadass Jessy Mercy
BDBalasubramanian Deepika
Balasubramanian Deepika
KGKoyeli Girigoswami
Koyeli Girigoswami

13 June 2025 in Chemistry
Verified
Journal Article
Open access
PDF file
SUSaranya Udayakumar
Saranya Udayakumar
SPShangavy Pandiarajan
Shangavy Pandiarajan
DMDevadass Jessy Mercy
Devadass Jessy Mercy
JSJayaprakash Suresh
Jayaprakash Suresh
JJJashwanth raj J
Jashwanth raj J
KGKoyeli Girigoswami
Koyeli Girigoswami
Developing an effective vaccine that is safer is the main focus in the field of cancer immunotherapy. Among other therapeutic approaches, cancer nanovaccination is formulated to deliver tumor adjuvant or antigen to the antigen-presenting cells (APCs) to prevent cancer relapse and metastasis. It has shown excellent efficacy in inhibiting cancer growth. Herein, we discussed various forms of nanovaccines, including lipid-based nanovaccines, metal-based nanovaccines, carbon nanotube-based nanovaccines, PLGA-based nanovaccines, exosome-based nanovaccines, dendritic cell-based nanovaccines, and self-adjuvant nanovaccines in cancer immunotherapy, including their therapeutic effect. We expect that the investigated content will provide a valuable reference for future research and the development of nanovaccines for cancer treatment.

23 December 2025 in Physchem
Verified
Journal Article
Open access
PDF file
DSDhruv Suraneni
Dhruv Suraneni
BDBalasubramanian Deepika
Balasubramanian Deepika
KMKavinithi Jaganathan Mahadevan
Kavinithi Jaganathan Mahadevan
SRSanjana Raghupathy
Sanjana Raghupathy
SPShangavy Pandiarajan
Shangavy Pandiarajan
KGKoyeli Girigoswami
Koyeli Girigoswami
The field of nanotechnology has witnessed a paradigm shift towards eco-friendly and sustainable synthesis methods for nanoparticles due to increasing concerns over environmental toxicity and resource sustainability. Among various metal oxide nanoparticles, zirconium dioxide (ZrO2) nanoparticles have garnered significant attention owing to their exceptional thermal stability, biocompatibility, mechanical strength, and catalytic properties. Doping ZrO2 with transition metals such as copper (Cu) further enhances its physicochemical attributes, including antibacterial activity, redox behaviour, and electronic properties, rendering it suitable for a diverse range of biomedical and industrial applications. In the present study, we report the green synthesis of copper-doped ZrO2 nanoparticles (Cu-ZrO2-CO NPs) using an aqueous extract of Calendula officinalis (marigold) flowers as a natural reducing and stabilizing agent. The complete characterization was performed using UV–vis spectrophotometry, dynamic light scattering (DLS), zeta potential, FTIR, SEM, EDAX, and XRD, revealing its size to be around 20–40 nm and zeta potential as −20 mV, indicating nano size and stability. The biocompatibility of the as-synthesized nanoparticle was analyzed in vitro using fibroblast cell viability and haemolysis assay, and in vivo using brine shrimp assay. The nanoparticles were safe up to a dose of 50 μg/mL, showing more than 95% cell viability and less than 2% haemolysis, which is within an acceptable range. Finally, the anticancer activity was explored for A549 cells by MTT assay and live-dead assay, with an IC50 value of 38.63 μg/mL. The chorioallantoic membrane (CAM) model was used to assess the anti-angiogenesis potential of the Cu-ZrO2-CO NPs. The results showed that the nanoparticles could kill the cancer cells via apoptosis, and one of the reasons for the anticancer effect was angiogenesis inhibition. Further research is needed using other cancer cell lines and animal tumour models.

11 October 2026 in Next Nanotechnology
Verified
Journal Article
Open access
SPShangavy Pandiarajan
Shangavy Pandiarajan
VKVenkatakrishnan Kiran
Venkatakrishnan Kiran
KGKoyeli Girigoswami
Koyeli Girigoswami
Agnishwar GirigoswamiAgnishwar Girigoswami
Agnishwar Girigoswami